GB0221582D0 - Method of treatment - Google Patents

Method of treatment

Info

Publication number
GB0221582D0
GB0221582D0 GBGB0221582.0A GB0221582A GB0221582D0 GB 0221582 D0 GB0221582 D0 GB 0221582D0 GB 0221582 A GB0221582 A GB 0221582A GB 0221582 D0 GB0221582 D0 GB 0221582D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0221582.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Priority to GBGB0221582.0A priority Critical patent/GB0221582D0/en
Publication of GB0221582D0 publication Critical patent/GB0221582D0/en
Priority to JP2004537394A priority patent/JP2006501276A/en
Priority to MXPA05002912A priority patent/MXPA05002912A/en
Priority to BR0314381-3A priority patent/BR0314381A/en
Priority to CA002495311A priority patent/CA2495311A1/en
Priority to AU2003259464A priority patent/AU2003259464A1/en
Priority to PCT/IB2003/003905 priority patent/WO2004026312A1/en
Priority to EP03797435A priority patent/EP1545541A1/en
Priority to PL03374730A priority patent/PL374730A1/en
Priority to CNA038219786A priority patent/CN1681506A/en
Priority to KR1020057004463A priority patent/KR20050057349A/en
Priority to TW092125390A priority patent/TW200409770A/en
Priority to US10/667,119 priority patent/US20040116451A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB0221582.0A 2002-09-17 2002-09-17 Method of treatment Ceased GB0221582D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB0221582.0A GB0221582D0 (en) 2002-09-17 2002-09-17 Method of treatment
KR1020057004463A KR20050057349A (en) 2002-09-17 2003-09-04 Use of a quinazoline derivative for treating lower urinary tract symptoms
PCT/IB2003/003905 WO2004026312A1 (en) 2002-09-17 2003-09-04 Use of a quinazoline derivative for treating lower urinary tract symptoms
MXPA05002912A MXPA05002912A (en) 2002-09-17 2003-09-04 Use of a quinazoline derivative for treating lower urinary tract symptoms.
BR0314381-3A BR0314381A (en) 2002-09-17 2003-09-04 Use of a quinazoline derivative to treat lower urinary tract symptoms
CA002495311A CA2495311A1 (en) 2002-09-17 2003-09-04 Use of a quinazoline derivative for treating lower urinary tract symptoms
AU2003259464A AU2003259464A1 (en) 2002-09-17 2003-09-04 Use of a quinazoline derivative for treating lower urinary tract symptoms
JP2004537394A JP2006501276A (en) 2002-09-17 2003-09-04 Use of quinazoline derivatives for the treatment of lower ureteral signs
EP03797435A EP1545541A1 (en) 2002-09-17 2003-09-04 Use of a quinazoline derivative for treating lower urinary tract symptoms
PL03374730A PL374730A1 (en) 2002-09-17 2003-09-04 Use of a quinazoline derivative for treating lower urinary tract symptoms
CNA038219786A CN1681506A (en) 2002-09-17 2003-09-04 Use of a quinazoline derivative for treating lower urinary tract symptoms
TW092125390A TW200409770A (en) 2002-09-17 2003-09-15 Pharmaceutical composition for the treatment of LUTS
US10/667,119 US20040116451A1 (en) 2002-09-17 2003-09-17 Method of treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0221582.0A GB0221582D0 (en) 2002-09-17 2002-09-17 Method of treatment

Publications (1)

Publication Number Publication Date
GB0221582D0 true GB0221582D0 (en) 2002-10-23

Family

ID=9944253

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0221582.0A Ceased GB0221582D0 (en) 2002-09-17 2002-09-17 Method of treatment

Country Status (12)

Country Link
EP (1) EP1545541A1 (en)
JP (1) JP2006501276A (en)
KR (1) KR20050057349A (en)
CN (1) CN1681506A (en)
AU (1) AU2003259464A1 (en)
BR (1) BR0314381A (en)
CA (1) CA2495311A1 (en)
GB (1) GB0221582D0 (en)
MX (1) MXPA05002912A (en)
PL (1) PL374730A1 (en)
TW (1) TW200409770A (en)
WO (1) WO2004026312A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the manufacture of a medicament for the treatment of benign prostatic hyperplasia
AP2002002611A0 (en) * 2000-03-03 2002-09-30 Pfizer 4-Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline mesylat and polymorphs.

Also Published As

Publication number Publication date
MXPA05002912A (en) 2005-09-30
CA2495311A1 (en) 2004-04-01
CN1681506A (en) 2005-10-12
PL374730A1 (en) 2005-10-31
AU2003259464A1 (en) 2004-04-08
BR0314381A (en) 2005-07-19
EP1545541A1 (en) 2005-06-29
JP2006501276A (en) 2006-01-12
WO2004026312A1 (en) 2004-04-01
TW200409770A (en) 2004-06-16
KR20050057349A (en) 2005-06-16

Similar Documents

Publication Publication Date Title
GB2393202B (en) Methods of well treatment
AU2003226301A8 (en) Method of treating cancer
AU2003278361A1 (en) Method of water treatment
IL164266A0 (en) Treatment of gastroparesis
EP1577280A4 (en) Method of deuterization
ZA200409331B (en) Method of treating diabetes
GB0302572D0 (en) Method of treatment
GB0306309D0 (en) Method of treatment
EP1389105A4 (en) Method of treatment
GB0124124D0 (en) Methods of treatment
GB0112216D0 (en) Method of treatment
EP1493716A4 (en) Method of wastewater treatment
GB0208897D0 (en) New method of treatment
GB0118892D0 (en) Method of treatment
GB0217493D0 (en) Novel methods of treatment
GB0221712D0 (en) Methods of treatment
PL376350A1 (en) Sludge treatment method
AU2002951913A0 (en) Method of treatment
AU2003252188A8 (en) Method of ore treatment
GB0213198D0 (en) Method of treatment
GB0327975D0 (en) Methods of treatment
GB0207091D0 (en) Method of treatment
GB0307544D0 (en) Treatment method
GB0226275D0 (en) Method of treatment
GB0206699D0 (en) Method of treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)